Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and clinical outcomes of percutaneous coronary intervention PCI for chronic total occlusions CTO in patients treated in routine clinical practice in Poland. The study seeks to understand procedural success rates, complications, and how different PCI strategies, intravascular imaging, mechanical support, and artificial intelligence analysis impact patient outcomes and quality of life. It also focuses on outcomes in various patient subgroups, including those with complex medical histories. This observational study enrolls patients undergoing CTO PCI as part of their standard care in a national, multicenter registry. Clinical, procedural, and follow-up data are collected prospectively to assess real-world outcomes. The study compares PCI performed with and without intravascular imaging and evaluates different treatment strategies such as drug-coated balloons, drug-eluting stents, and hybrid approaches. It also monitors the use of mechanical circulatory support and applies AI-based analysis of baseline electrocardiograms for outcome prediction. Participants will be followed to measure technical success of the procedure and monitor procedural details such as procedure time, fluoroscopy time, radiation dose, contrast volume, and procedural complications within one day. Additional outcomes include target lesion failure during hospital stay and up to one year, as well as mortality at one year. The study collects information on post-procedure cardiac injury markers and quality-of-life improvements, with data gathered throughout routine clinical care over the follow-up period.